• MMP is the most critical protease which is involved in

  2024-06-05

  

  MMP9 is the most critical protease which is involved in the degradation of ECM. TIMP-1 is an important regulator in the synthesis and degradation of ECM [8,9]. Hepatic TIMP-1 expression significantly increases in patients with liver fibrosis [10]. Serum level of TIMP-1 expression is positively assoc

• lipid metabolism The protein kinase CK mediated phosphorylat

  2024-06-05

  

  The protein kinase CK2-mediated phosphorylation of HMGN1 was implicated to be involved in age-associated amnesia in rats [31]. It was shown that the decreased level of HMGN1 phosphorylation due to the down-regulation of CK2 activity could cause amnesia in aged rats, whereas the treatment with protei

• br Declarations Funding None for the paper in question Compe

  2024-06-05

  

  Declarations Funding: None for the paper in question. Competing interests: Florent Morio has received speaker's fees from Gilead, Basilea, and MSD and travel grants from Gilead, MSD, Pfizer, Basilea, and Astellas. Ethical approval: Not relevant for the paper in question. Introduction Lactic

• crizotinib synthesis RNA interference assays have shown that

  2024-06-05

  

  RNA interference assays have shown that the inhibition of AMPK expression leads to increases in TNF-α, IL-6 and cyclooxygenase-2 (COX-2) levels after LPS stimulus, whereas the transfection of macrophages with a constitutively active form of AMPKα1 results in decreased LPS-induced TNF-α and IL-6 prod

• A disfun o cognitiva p s operat ria uma

  2024-06-05

  

  A disfunção cognitiva pós‐operatória é uma síndrome perioperatória bem reconhecida, consequência da anestesia e cirurgia cuja causa exata permanece por esclarecer. De que forma nigericin disfunção cognitiva pós‐operatória e a doença de Alzheimer podem estar ligadas permanece uma questão em estudo. A

• Chrysin MD was the recipient of

  2024-06-05

  

  MD was the recipient of the Intergroupe Francophone de Cancérologie Thoracique (IFCT) Alain Depierre Grant in 2014. JP was the recipient of the ARISTOT (Association de Recherche, d’Information Scientifique et Thérapeutique en Oncologie Thoracique) grant in 2016. Conflicts of interest statement

• Recently a Phase III study demonstrated that alectinib

  2024-06-05

  

  Recently, a Phase III study demonstrated that alectinib, the second-generation ALK inhibitor, might have a better response to ALK-rearrangement patients than crizotinib [10]. Should alectinib replace crizotinib as the frontline treatment for ALK-rearranged patients? Or should those patients be treat

• While the mechanisms by which ALDH regulates cardiac respons

  2024-06-05

  

  While the mechanisms by which ALDH2 regulates cardiac responses to pathological stress remain unclear, the capillary rarefaction found in pressure-overloaded ALDH2 Tg hearts provides potential clues. Loss of capillary density and diminished endothelial function occur in pathological hypertrophy [46]

• It is well known that TCDD is the most

  2024-06-05

  

  It is well-known that TCDD is the most potent ligand of AhR and it regulates gene expression, such as CYP1A1, via activation of AhR (Mimura and Fujii-Kuriyama, 2003). Besides Tomblin et al. (2016) have recently shown that TCDD via AhR regulated L-type amino EMD638683 transporter 1 expression in MCF

• br AChE variants and their

  2024-06-04

  

  AChE variants and their functions The AChE gene generates several splice variants of AChE which are designated as hydrophobic (H), readthrough (R) and tailed (T) forms differing in membrane association and also localisation on a tissue and sub-cellular level. They all undergo significant posttran

• An alternative to the agonist or antagonist potential

  2024-06-04

  

  An alternative to the agonist or antagonist potential in drug discovery is the positive allosteric modulator (PAM) approach, which can augment the normal processes of neurotransmission as opposed to directly replacing or antagonizing them. PAMs are thought to bind to sites that are distinct from the

• What can we learn about the anticancer

  2024-06-04

  

  What can we learn about the anticancer therapeutic efficacy of Aurora kinase inhibitors from our experience with the Bcr-Abl inhibitors and the long term clinical consequence of their use in treating leukemias? As discussed, all Aurora kinase inhibitors developed to date are ATP-competitive inhibito

• Although several different membrane estrogen receptors have

  2024-06-04

  

  Although several different membrane estrogen receptors have been reported (Qiu et al., 2008; Revankar et al., 2005), a large percentage of membrane-initiated steroid hormone signaling appears to be performed by a subpopulation of the same receptors that act in the nucleus. Specifically, estrogen rec

• ASK has been identified as an ASK

  2024-06-04

  

  ASK2 has been identified as an ASK1 binding protein (Wang et al., 1998). ASK1 supports the stability and active configuration of ASK2 in the heteromeric complex, while ASK2 has been found to activate ASK1 by direct phosphorylation (Takeda et al., 2007). Unlike ASK1, which is ubiquitously expressed i

• br Emerging Vascular Mechanisms of AA Therapy Resistance Exp

  2024-06-04

  

  Emerging Vascular Mechanisms of AA Therapy Resistance Experimental and clinical evidence indicates that physiological angiogenesis generates blood vessels capable of restoring perfusion [1], whereas tumoral angiogenesis gives rise to vessels that are structurally and functionally abnormal, therei

16349 records 140/1090 page Previous Next First page 上5页 136137138139140 下5页 Last page